FDA Brief

Warning letters Drugs

FDA warning letter to

Vitae Enim Vitae Scientific Inc.

High riskIssued Mar 17, 2022Posted Apr 26, 2022Division of Pharmaceutical Quality Operations IV

FDA warned Vitae Enim Vitae Scientific of sterile drug CGMP violations and contamination-control failures after a 2021 inspection, leading to a recall.

What happened

FDA inspected Vitae Enim Vitae Scientific’s San Diego drug manufacturing facility from September 13 to 22, 2021, and found significant CGMP violations for sterile drug production. The letter cites missing smoke studies, deficient environmental monitoring, inadequate quality-unit oversight of a contract testing laboratory and suppliers, incomplete investigations, and insufficient visual inspection. The company initiated a recall of all products intended to be sterile that are within expiry after discussions with FDA, and FDA called the company’s October 11, 2021 response inadequate.

What FDA found

  1. The company lacked required procedures to prevent microbiological contamination of sterile drugs, had not performed smoke studies before the inspection, and had aseptic-line design and gowning problems.

    21 CFR 211.113(b)
  2. The company’s environmental monitoring in aseptic areas was deficient, including no active viable air sampling during aseptic processing and procedures missing alert levels, sampling details, deviation response, and trend review.

    21 CFR 211.42(c)(10)(iv)
  3. The quality control unit failed to oversee the contract testing laboratory’s method validation and failed to adequately qualify a new sterile supplier and evaluate a specification change.

    21 CFR 211.22
  4. The company did not thoroughly investigate ink leaching from tubing into drug solution, including root cause, affected batches, and contaminant toxicity.

    21 CFR 211.192
  5. The company’s visual inspection of aseptically filled drug products was insufficient, with few vials inspected, no solid color backgrounds, and no procedures.

    21 CFR 211.110(a)

What FDA wants

FDA asks the company to provide independent assessments and detailed remediation plans for contamination hazards, environmental monitoring, contract laboratory and supplier oversight, investigations, and visual inspection, plus a full visual inspection of retain samples. FDA says to notify it before resuming sterile production, after third-party verification; the letter does not state a response deadline.

Who should pay attention

  • patients and clinicians using sterile drugs
  • companies that rely on contract sterile drug manufacturers
  • contract testing laboratories and suppliers serving sterile drug makers

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Hanlim Pharm Co., Ltd.

    FDA warned Hanlim Pharm over serious sterile manufacturing violations, including poor aseptic practices and airflow problems, at its South Korea plant.

    High risk
  2. Sciarra Aeromed, Inc.

    Sciarra Aeromed's purportedly sterile veterinary drug was contaminated and made under insanitary conditions, FDA says.

    High risk
  3. Empower Clinic Services, LLC dba Empower Pharmacy

    FDA warned Empower Pharmacy over unapproved compounded semaglutide/tirzepatide copies and sterile manufacturing deficiencies that put patients at risk.

    High risk
  4. Bausch & Lomb Inc.

    FDA warns Bausch & Lomb of persistent microbial contamination and poor aseptic controls at its Tampa sterile drug plant.

    High risk